A full list of members is provided in the Acknowledgments.
Critical Review and Invited Commentary
Recommendations for HLA-B*15:02 and HLA-A*31:01 genetic testing to reduce the risk of carbamazepine-induced hypersensitivity reactions
Article first published online: 5 MAR 2014
Wiley Periodicals, Inc. © 2014 International League Against Epilepsy
Volume 55, Issue 4, pages 496–506, April 2014
How to Cite
Epilepsia, 55(4):496–506, 2014
- Issue published online: 22 APR 2014
- Article first published online: 5 MAR 2014
- Manuscript Accepted: 14 JAN 2014
- Canadian Institutes of Health Research (CIHR) Meetings, Planning and Dissemination Grant — Knowledge Translation Supplement
- FRN. Grant Number: 114403
|epi12564-sup-0001-Supporting Information.docx||Word document||299K|
Data S1. Glossary: Definitions and abbreviations used throughout the document.
Table S1. Summary table of evidence regarding the association of HLA-B*15:02 with CBZ-induced SJS/TEN.
Table S2. Population frequencies of HLA-B*15:02.
Table S3. Summary table of evidence regarding the association of HLA-A*31:01 with CBZ-induced HSS and MPE.
Table S4. Summary table of evidence regarding the association of HLA-A*31:01 with CBZ-induced SJS/TEN.
Table S5. Population frequencies of HLA-A*31:01.
Data S2. Supplementary methods: Additional details on the evidence review and clinical practice recommendation development, including the systematic literature search strategy.
Data S3. Test availability: A brief discussion of test availability for HLA-B*15:02 and HLA-A*31:01.
Data S4. Quick reference document: Summary of key messages and recommendations in bullet point format.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.